Literature DB >> 11711056

The cannabinoid receptor antagonist SR 141716 prevents acquisition of drinking behavior in alcohol-preferring rats.

S Serra1, M A Carai, G Brunetti, R Gomez, S Melis, G Vacca, G Colombo, G L Gessa.   

Abstract

The cannabinoid CB(1) receptor antagonist, N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazole-carboxamide) (SR 141716); 0.3-3 mg/kg, i.p., twice daily for 10 days), prevented the acquisition of alcohol drinking behavior in rats genetically selected for alcohol preference (Sardinian alcohol-preferring (sP) rats), having the free choice between alcohol (10%, v/v) and water. The results suggest that activation of cannabinoid CB(1) receptors is essential for the acquisition of alcohol drinking behavior in animals with a genetically determined alcohol preference.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11711056     DOI： 10.1016/s0014-2999(01)01379-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN： 0014-2999            Impact factor:   4.432


  26 in total

1.  Role of the endocannabinoid system in MDMA intracerebral self-administration in rats.

Authors:  Daniela Braida; Mariaelvina Sala
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

2.  Cannabinoid CB1 receptor inhibition blunts adolescent-typical increased binge alcohol and sucrose consumption in male C57BL/6J mice.

Authors:  Abigail E Agoglia; Sarah E Holstein; Vallari R Eastman; Clyde W Hodge
Journal:  Pharmacol Biochem Behav       Date:  2016-01-19       Impact factor: 3.533

Review 3.  The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence.

Authors:  Giancarlo Colombo; Alessandro Orrù; Paola Lai; Claudia Cabras; Paola Maccioni; Marina Rubio; Gian Luigi Gessa; Mauro A M Carai
Journal:  Mol Neurobiol       Date:  2007-07-03       Impact factor: 5.590

4.  Innate difference in the endocannabinoid signaling and its modulation by alcohol consumption in alcohol-preferring sP rats.

Authors:  K Yaragudri Vinod; Paola Maccioni; Maria Salud Garcia-Gutierrez; Teresa Femenia; Shan Xie; Mauro A M Carai; Jorge Manzanares; Thomas B Cooper; Basalingappa L Hungund; Giancarlo Colombo
Journal:  Addict Biol       Date:  2011-02-11       Impact factor: 4.280

Review 5.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

Review 6.  Minireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation.

Authors:  Robert P Picone; Debra A Kendall
Journal:  Mol Endocrinol       Date:  2015-04-13

7.  Inhibition of 5alpha-reduced steroid biosynthesis impedes acquisition of ethanol drinking in male C57BL/6J mice.

Authors:  Matthew M Ford; Naomi Yoneyama; Moriah N Strong; Andrea Fretwell; Michelle Tanchuck; Deborah A Finn
Journal:  Alcohol Clin Exp Res       Date:  2008-06-28       Impact factor: 3.455

8.  Long-lasting increase of alcohol relapse by the cannabinoid receptor agonist WIN 55,212-2 during alcohol deprivation.

Authors:  José Antonio López-Moreno; Gustavo González-Cuevas; Fernando Rodríguez de Fonseca; Miguel Navarro
Journal:  J Neurosci       Date:  2004-09-22       Impact factor: 6.167

Review 9.  Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity.

Authors:  Richard L Bell; Helen J K Sable; Giancarlo Colombo; Petri Hyytia; Zachary A Rodd; Lawrence Lumeng
Journal:  Pharmacol Biochem Behav       Date:  2012-07-25       Impact factor: 3.533

10.  Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon.

Authors:  Angelo A Izzo; Gabriella Aviello; Stefania Petrosino; Pierangelo Orlando; Giovanni Marsicano; Beat Lutz; Francesca Borrelli; Raffaele Capasso; Santosh Nigam; Francesco Capasso; Vincenzo Di Marzo
Journal:  J Mol Med (Berl)       Date:  2007-09-06       Impact factor: 4.599
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.